Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $439.8 million.

  • Allogene Therapeutics' Liabilities and Shareholders Equity fell 2535.12% to $439.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year decrease of 2020.67%. This contributed to the annual value of $548.7 million for FY2024, which is 1464.24% down from last year.
  • Allogene Therapeutics' Liabilities and Shareholders Equity amounted to $439.8 million in Q3 2025, which was down 2535.12% from $470.6 million recorded in Q2 2025.
  • Allogene Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $1.2 billion for Q1 2021, and its period low was $439.8 million during Q3 2025.
  • In the last 5 years, Allogene Therapeutics' Liabilities and Shareholders Equity had a median value of $750.1 million in 2023 and averaged $776.5 million.
  • As far as peak fluctuations go, Allogene Therapeutics' Liabilities and Shareholders Equity skyrocketed by 7124.25% in 2021, and later tumbled by 2725.22% in 2025.
  • Allogene Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $1.1 billion in 2021, then decreased by 21.82% to $821.6 million in 2022, then dropped by 21.76% to $642.8 million in 2023, then dropped by 14.64% to $548.7 million in 2024, then dropped by 19.85% to $439.8 million in 2025.
  • Its Liabilities and Shareholders Equity was $439.8 million in Q3 2025, compared to $470.6 million in Q2 2025 and $508.0 million in Q1 2025.